Publications

1. Holditch SJ, Schreiber CA, Harris PC, LaRusso NF, Ramirez-Alvarado M, Cataliotti A, Torres VE, Ikeda Y. B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease. Kidney Int. 2017 Sep; 92 (3):657-668 Epub 2017 Apr 14
   View PubMed
2. Holditch SJ, Schreiber CA, Nini R, Tonne JM, Peng KW, Geurts A, Jacob HJ, Burnett JC, Cataliotti A, Ikeda Y. B-Type Natriuretic Peptide Deletion Leads to Progressive Hypertension, Associated Organ Damage, and Reduced Survival: Novel Model for Human Hypertension. Hypertension. 2015 Jul; 66 (1):199-210 Epub 2015 May 11
   View PubMed
3. Bellavia D, Cataliotti A, Clemenza F, Baravoglia CH, Luca A, Traina M, Gridelli B, Bertani T, Burnett JC, Scardulla C. Long-Term Structural and Functional Myocardial Adaptations in Healthy Living Kidney Donors: A Pilot Study. PLoS One. 2015; 10 (11):e0142103 Epub 2015 Nov 10
   View PubMed
4. Buglioni A, Cannone V, Cataliotti A, Sangaralingham SJ, Heublein DM, Scott CG, Bailey KR, Rodeheffer RJ, Dessi-Fulgheri P, Sarzani R, Burnett JC Jr. Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease. Hypertension. 2015 Jan; 65 (1):45-53 Epub 2014 Nov 03
   View PubMed
5. Tonne JM, Holditch SJ, Oehler EA, Schreiber CA, Ikeda Y, Cataliotti A. Cardiac BNP gene delivery prolongs survival in aged spontaneously hypertensive rats with overt hypertensive heart disease. Aging (Albany NY). 2014 Apr; 6 (4):311-9
   View PubMed
6. McKie PM, Cataliotti A, Ichiki T, Sangaralingham SJ, Chen HH, Burnett JC Jr. M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics. J Am Heart Assoc. 2014 Jan 2; 3 (1):e000206 Epub 2014 Jan 02
   View PubMed
7. Aspelin T, Eriksen M, Ilebekk A, Cataliotti A, Carlson CR, Lyberg T. β-blockade abolishes the augmented cardiac tPA release induced by transactivation of heterodimerized bradykinin receptor-2 and β2-adrenergic receptor in vivo. Thrombosis and Homeostasis. 2014.
   
8. Ichiki T, Izumi R, Cataliotti A, Larsen AM, Sandberg SM, Burnett JC Jr. Endothelial permeability in vitro and in vivo: protective actions of ANP and omapatrilat in experimental atherosclerosis. Peptides. 2013 Oct; 48:21-6 Epub 2013 Aug 06
   View PubMed
9. Mangiafico S, Costello-Boerrigter LC, Andersen IA, Cataliotti A, Burnett JC Jr. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J. 2013 Mar; 34 (12):886-893c Epub 2012 Aug 31
   View PubMed
10. Chen HH, Glockner JF, Schirger JA, Cataliotti A, Redfield MM, Burnett JC Jr. Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide. J Am Coll Cardiol. 2012 Dec 4; 60 (22):2305-12 Epub 2012 Nov 01
    View PubMed
11. Macheret F, Heublein D, Costello-Boerrigter LC, Boerrigter G, McKie P, Bellavia D, Mangiafico S, Ikeda Y, Bailey K, Scott CG, Sandberg S, Chen HH, Malatino L, Redfield MM, Rodeheffer R, Burnett J Jr, Cataliotti A. Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP. J Am Coll Cardiol. 2012 Oct 16; 60 (16):1558-65
    View PubMed
12. Martin FL, McKie PM, Cataliotti A, Sangaralingham SJ, Korinek J, Huntley BK, Oehler EA, Harders GE, Ichiki T, Mangiafico S, Nath KA, Redfield MM, Chen HH, Burnett JC Jr. Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection. Am J Physiol Regul Integr Comp Physiol. 2012 Jan 15; 302 (2):R292-9 Epub 2011 Nov 09
    View PubMed
13. McKie PM, Cataliotti A, Sangaralingham SJ, Ichiki T, Cannone V, Bailey KR, Redfield MM, Rodeheffer RJ, Burnett JC Jr. Predictive utility of atrial, N-terminal pro-atrial, and N-terminal pro-B-type natriuretic peptides for mortality and cardiovascular events in the general community: a 9-year follow-up study. Mayo Clin Proc. 2011 Dec; 86 (12):1154-60
    View PubMed
14. Sangaralingham SJ, Heublein DM, Grande JP, Cataliotti A, Rule AD, McKie PM, Martin FL, Burnett JC Jr. Urinary C-type natriuretic peptide excretion: a potential novel biomarker for renal fibrosis during aging. Am J Physiol Renal Physiol. 2011 Nov; 301 (5):F943-52 Epub 2011 Aug 24
    View PubMed
15. Cannone V, Boerrigter G, Cataliotti A, Costello-Boerrigter LC, Olson TM, McKie PM, Heublein DM, Lahr BD, Bailey KR, Averna M, Redfield MM, Rodeheffer RJ, Burnett JC Jr. A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community. J Am Coll Cardiol. 2011 Aug 2; 58 (6):629-36
    View PubMed
16. Tonne JM, Campbell JM, Cataliotti A, Ohmine S, Thatava T, Sakuma T, Macheret F, Huntley BK, Burnett JC Jr, Ikeda Y. Secretion of glycosylated pro-B-type natriuretic peptide from normal cardiomyocytes. Clin Chem. 2011 Jun; 57 (6):864-73 Epub 2011 Apr 11
    View PubMed
17. Cataliotti A, Tonne JM, Bellavia D, Martin FL, Oehler EA, Harders GE, Campbell JM, Peng KW, Russell SJ, Malatino LS, Burnett JC Jr, Ikeda Y. Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats. Circulation. 2011 Mar 29; 123 (12):1297-305 Epub 2011 Mar 14
    View PubMed
18. Macheret F, Boerrigter G, McKie P, Costello-Boerrigter L, Lahr B, Heublein D, Sandberg S, Ikeda Y, Cataliotti A, Bailey K, Rodeheffer R, Burnett JC Jr. Pro-B-type natriuretic peptide(1-108) circulates in the general community: plasma determinants and detection of left ventricular dysfunction. J Am Coll Cardiol. 2011 Mar 22; 57 (12):1386-95
    View PubMed
19. McKie PM, Cataliotti A, Boerrigter G, Chen HH, Sangaralingham SJ, Martin FL, Ichiki T, Burnett JC Jr. A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension. Hypertension. 2010 Dec; 56 (6):1152-9 Epub 2010 Oct 25
    View PubMed
20. McKie PM, Cataliotti A, Lahr BD, Martin FL, Redfield MM, Bailey KR, Rodeheffer RJ, Burnett JC Jr. The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects. J Am Coll Cardiol. 2010 May 11; 55 (19):2140-7
    View PubMed
21. Costello-Boerrigter LC, Boerrigter G, Cataliotti A, Harty GJ, Burnett JC Jr. Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure. Circ Heart Fail. 2010 May; 3 (3):412-9 Epub 2010 Feb 22
    View PubMed
22. McKie PM, Cataliotti A, Huntley BK, Martin FL, Olson TM, Burnett JC Jr. A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions. J Am Coll Cardiol. 2009 Sep 8; 54 (11):1024-32
    View PubMed
23. Chen HH, Martin FL, Gibbons RJ, Schirger JA, Wright RS, Schears RM, Redfield MM, Simari RD, Lerman A, Cataliotti A, Burnett JC Jr. Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept study. Heart. 2009 Aug; 95 (16):1315-9 Epub 2009 May 15
    View PubMed
24. Boerrigter G, Costello-Boerrigter LC, Harty GJ, Huntley BK, Cataliotti A, Lapp H, Burnett JC Jr. B-type natriuretic peptide 8-32, which is produced from mature BNP 1-32 by the metalloprotease meprin A, has reduced bioactivity. Am J Physiol Regul Integr Comp Physiol. 2009 Jun; 296 (6):R1744-50 Epub 2009 Apr 22
    View PubMed
25. Chen HH, Cataliotti A, Schirger JA, Martin FL, Harstad LK, Burnett JC Jr. Local renal delivery of a natriuretic peptide a renal-enhancing strategy for B-type natriuretic peptide in overt experimental heart failure. J Am Coll Cardiol. 2009 Apr 14; 53 (15):1302-8
    View PubMed
26. Martin FL, Chen HH, Cataliotti A, Burnett JC Jr. Targeting the kidney in acute decompensated heart failure: conventional diuretics and renal-acting vasodilators. Rev Cardiovasc Med. 2008 Winter; 9(1):39-45.
    View PubMed
27. Cataliotti A, Chen HH, Schirger JA, Martin FL, Boerrigter G, Costello-Boerrigter LC, James KD, Polowy K, Miller MA, Malkar NB, Bailey KR, Burnett JC Jr. Chronic actions of a novel oral B-type natriuretic peptide conjugate in normal dogs and acute actions in angiotensin II-mediated hypertension. Circulation. 2008 Oct 21; 118 (17):1729-36 Epub 2008 Oct 06
    View PubMed
28. Martin FL, Chen HH, Cataliotti A, Burnett JC Jr. B-type natriuretic peptide: beyond a diagnostic. Heart Fail Clin. 2008 Oct; 4 (4):449-54
    View PubMed
29. Costello-Boerrigter LC, Boerrigter G, Harty GJ, Cataliotti A, Redfield MM, Burnett JC Jr. Mineralocorticoid escape by the kidney but not the heart in experimental asymptomatic left ventricular dysfunction. Hypertension. 2007 Sep; 50: (3)481-8.
    View PubMed
30. Heublein DM, Huntley BK, Boerrigter G, Cataliotti A, Sandberg SM, Redfield MM, Burnett JC Jr. Immunoreactivity and guanosine 3',5'-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension. 2007 May; 49: (5)1114-9.
    View PubMed
31. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Lapp H, Stasch JP, Burnett JC Jr. Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension. 2007 May; 49: (5)1128-33.
    View PubMed
32. Huntley BK, Sandberg SM, Noser JA, Cataliotti A, Redfield MM, Matsuda Y, Burnett JC Jr. BNP-induced activation of cGMP in human cardiac fibroblasts: interactions with fibronectin and natriuretic peptide receptors. J Cell Physiol. 2006 Dec; 209: (3)943-9.
    View PubMed
33. Chen HH, Schirger JA, Cataliotti A, Burnett JC Jr. Intact acute cardiorenal and humoral responsiveness following chronic subcutaneous administration of the cardiac peptide BNP in experimental heart failure. Eur J Heart Fail. 2006 Nov; 8(7):681-6. Epub 2006 Feb 03.
    View PubMed
34. Belluardo P, Cataliotti A, Bonaiuto L, Giuffre E, Maugeri E, Noto P, Orlando G, Raspa G, Piazza B, Babuin L, Chen HH, Martin FL, McKie PM, Heublein DM, Burnett JC, Malatino LS. Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2006 Oct; 291(4):H1529-35. Epub 2006 Apr 28.
    View PubMed
35. Chen HH, Huntley BK, Schirger JA, Cataliotti A, Burnett JC Jr. Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure. J Am Soc Nephrol. 2006 Oct; 17 (10):2742-7 Epub 2006 Aug 23
    View PubMed
36. Cataliotti A, Chen HH, Redfield MM, Burnett JC Jr. Natriuretic peptides as regulators of myocardial structure and function: pathophysiologic and therapeutic implications. Heart Fail Clin. 2006 Jul; 2(3):269-76.
    View PubMed
37. McKie PM, Rodeheffer RJ, Cataliotti A, Martin FL, Urban LH, Mahoney DW, Jacobsen SJ, Redfield MM, Burnett JC Jr. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension. 2006 May; 47 (5):874-80 Epub 2006 Apr 03
    View PubMed
38. Bardelli M, Veglio F, Arosio E, Cataliotti A, Valvo E, Morganti A, Italian Group for the Study of Renovascular Hypertension. New intrarenal echo-Doppler velocimetric indices for the diagnosis of renal artery stenosis. Kidney Int. 2006 Feb; 69(3):580-7.
    View PubMed
39. Hawkridge AM, Heublein DM, Bergen HR 3rd, Cataliotti A, Burnett JC Jr, Muddiman DC. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A. 2005 Nov 29; 102 (48):17442-7 Epub 2005 Nov 17
    View PubMed
40. Cataliotti A, Burnett JC Jr. Natriuretic peptides: novel therapeutic targets in heart failure. J Investig Med. 2005 Nov; 53: (7)378-84.
    View PubMed
41. Cataliotti A, Schirger JA, Martin FL, Chen HH, McKie PM, Boerrigter G, Costello-Boerrigter LC, Harty G, Heublein DM, Sandberg SM, James KD, Miller MA, Malkar NB, Polowy K, Burnett JC Jr. Oral human brain natriuretic peptide activates cyclic guanosine 3',5'-monophosphate and decreases mean arterial pressure. Circulation. 2005 Aug 9; 112(6):836-40. Epub 2005 Aug 01.
    View PubMed
42. Chen HH, Cataliotti A, Schirger JA, Martin FL, Burnett JC Jr. Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure. Am J Physiol Regul Integr Comp Physiol. 2005 May; 288 (5):R1093-7 Epub 2004 Dec 30
    View PubMed
43. Martin FL, Stevens TL, Cataliotti A, Schirger JA, Borgeson DD, Redfield MM, Luchner A, Burnett JC Jr. Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure. Kidney Int. 2005 May; 67(5):1723-30.
    View PubMed
44. James KD, Cataliotti A, Schirger JA, Plonka S, Burnett JC Jr. Congestive heart failure: pharmacological agents and the potential of B-type natriuretic Peptide. Curr Med Chem. 2005; 12(12):1439-47.
    View PubMed
45. Cataliotti A, Boerrigter G, Costello-Boerrigter LC, Schirger JA, Tsuruda T, Heublein DM, Chen HH, Malatino LS, Burnett JC Jr. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation. 2004 Apr 6; 109(13):1680-5. Epub 2004 Mar 15.
    View PubMed
46. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B, Cataliotti A, Malatino LS. Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int. 2004 Apr; 65(4):1492-8.
    View PubMed
47. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Cataliotti A, Seminara G, Stancanelli B, Malatino LS. Prognostic value of echocardiographic indicators of left ventricular systolic function in asymptomatic dialysis patients. J Am Soc Nephrol. 2004 Apr; 15(4):1029-37.
    View PubMed
48. Panuccio V, Tripepi R, Tripepi G, Mallamaci F, Benedetto FA, Cataliotti A, Bellanuova I, Giacone G, Malatino LS, Zoccali C. Heart valve calcifications, survival, and cardiovascular risk in hemodialysis patients. Am J Kidney Dis. 2004 Mar; 43(3):479-84.
    View PubMed
49. Schirger JA, Chen HH, Jougasaki M, Lisy O, Boerrigter G, Cataliotti A, Burnett JC Jr. Endothelin A receptor antagonism in experimental congestive heart failure results in augmentation of the renin-angiotensin system and sustained sodium retention. Circulation. 2004 Jan 20; 109: (2)249-54.
    View PubMed
50. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Parlongo S, Cutrupi S, Iellamo D, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Malatino LS. Prospective study of neuropeptide y as an adverse cardiovascular risk factor in end-stage renal disease. J Am Soc Nephrol. 2003 Oct; 14(10):2611-7.
    View PubMed
51. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Parlongo S, Cutrupi S, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Malatino LS. Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease. J Hypertens. 2003 Jul; 21(7):1355-62.
    View PubMed
52. Jougasaki M, Leskinen H, Larsen AM, Luchner A, Cataliotti A, Tachibana I, Burnett JC Jr. Ventricular cardiotrophin-1 activation precedes BNP in experimental heart failure. Peptides. 2003 Jun; 24(6):889-92.
    View PubMed
53. Chen HH, Redfield MM, Nordstrom LJ, Cataliotti A, Burnett JC Jr. Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure. Am J Physiol Renal Physiol. 2003 May; 284(5):F1115-9.
    View PubMed
54. Tsuruda T, Jougasaki M, Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Lee SC, Salz-Gilman L, Nordstrom LJ, McGregor CG, Burnett JC. Ventricular adrenomedullin is associated with myocyte hypertrophy in human transplanted heart. Regul Pept. 2003 Apr 15; 112 (1-3):161-6
    View PubMed
55. Jougasaki M, Leskinen H, Larsen AM, Cataliotti A, Chen HH, Burnett JC Jr. Leukemia inhibitory factor is augmented in the heart in experimental heart failure. Eur J Heart Fail. 2003 Mar; 5(2):137-45.
    View PubMed
56. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Tsuruda T, Harty GJ, Lapp H, Stasch JP, Burnett JC Jr. Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Circulation. 2003 Feb 11; 107 (5):686-9
    View PubMed
57. Malatino LS, Cataliotti A, Benedetto FA, Stancanelli B, Bellanuova I, Belluardo P, Bonaiuto L, Tripepi G, Mallamaci F, Castellino P, Zoccali C. Hepatocyte growth factor and left ventricular geometry in end-stage renal disease. Hypertension. 2003 Jan; 41(1):88-92.
    View PubMed
58. Tsuruda T, Boerrigter G, Huntley BK, Noser JA, Cataliotti A, Costello-Boerrigter LC, Chen HH, Burnett JC Jr. Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res. 2002 Dec 13; 91 (12):1127-34
    View PubMed
59. Mallamaci F, Zoccali C, Parlongo S, Tripepi G, Benedetto FA, Cutrupi S, Bonanno G, Fatuzzo P, Rapisarda F, Seminara G, Stancanelli B, Bellanuova I, Cataliotti A, Malatino LS, Cardiovascular Risk Extended Evaluation in Dialysis Investigators. Diagnostic value of troponin T for alterations in left ventricular mass and function in dialysis patients. Kidney Int. 2002 Nov; 62(5):1884-90.
    View PubMed
60. Cataliotti A, Giordano M, De Pascale E, Giordano G, Castellino P, Jougasaki M, Costello LC, Boerrigter G, Tsuruda T, Belluardo P, Lee SC, Huntley B, Sandberg S, Malatino LS, Burnett JC Jr. CNP production in the kidney and effects of protein intake restriction in nephrotic syndrome. Am J Physiol Renal Physiol. 2002 Sep; 283(3):F464-72.
    View PubMed
61. Jougasaki M, Larsen AM, Cataliotti A, Christiansen DC, Burnett JC Jr. Cardiotrophin-1 stimulates endothelin-1 via gp130 in vascular endothelial cells. Peptides. 2002 Aug; 23(8):1441-7.
    View PubMed
62. Mallamaci F, Zoccali C, Parlongo S, Tripepi G, Benedetto FA, Cutrupi S, Bonanno G, Fatuzzo P, Rapisarda F, Seminara G, Stancanelli B, Bellanuova I, Cataliotti A, Malatino LS. Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2002 Jul; 40(1):68-75.
    View PubMed
63. Zoccali C, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Benedetto FA, Cataliotti A, Malatino LS, CREED investigators. Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension. 2002 Jul; 40(1):41-6.
    View PubMed
64. Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS, Cataliotti A, Bellanuova I, Boger R, CREED Investigators. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int. 2002 Jul; 62(1):339-45.
    View PubMed
65. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation. 2002 Mar 19; 105(11):1354-9.
    View PubMed
66. Tsuruda T, Jougasaki M, Boerrigter G, Huntley BK, Chen HH, D'Assoro AB, Lee SC, Larsen AM, Cataliotti A, Burnett JC Jr. Cardiotrophin-1 stimulation of cardiac fibroblast growth: roles for glycoprotein 130/leukemia inhibitory factor receptor and the endothelin type A receptor. Circ Res. 2002 Feb 8; 90 (2):128-34
    View PubMed
67. Cataliotti A, Boerrigter G, Chen HH, Jougasaki M, Costello LC, Tsuruda T, Lee SC, Malatino LS, Burnett JC Jr. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure. Circulation. 2002 Feb 5; 105 (5):639-44
    View PubMed
68. Mallamaci F, Zoccali C, Tripepi G, Fermo I, Benedetto FA, Cataliotti A, Bellanuova I, Malatino LS, Soldarini A, CREED Investigators. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int. 2002 Feb; 61(2):609-14.
    View PubMed
69. Castellino P, Cataliotti A. Changes of protein kinetics in nephrotic patients. Curr Opin Clin Nutr Metab Care. 2002 Jan; 5(1):51-4.
    View PubMed
70. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J, Boger R. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001 Dec 22-29; 358(9299):2113-7.
    View PubMed
71. Chen HH, Cataliotti A, Burnett JC Jr. Role of the natriuretic peptides in the cardiorenal and humoral actions of omapatrilat: insights from experimental heart failure. Curr Hypertens Rep. 2001 Dec; 3 Suppl 2:S15-21
    View PubMed
72. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Cataliotti A, Seminara G, Stancanelli B, Malatino LS, CREED Investigators. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol. 2001 Dec; 12(12):2768-74.
    View PubMed
73. Cataliotti A, Malatino LS, Jougasaki M, Zoccali C, Castellino P, Giacone G, Bellanuova I, Tripepi R, Seminara G, Parlongo S, Stancanelli B, Bonanno G, Fatuzzo P, Rapisarda F, Belluardo P, Signorelli SS, Heublein DM, Lainchbury JG, Leskinen HK, Bailey KR, Redfield MM, Burnett JC Jr. Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc. 2001 Nov; 76 (11):1111-9
    View PubMed
74. Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, Parlongo S, Cataliotti A, Cutrupi S, Giacone G, Bellanuova I, Cottini E, Malatino LS, Creed Investigators. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol. 2001 Jul; 12(7):1508-15.
    View PubMed
75. Mallamaci F, Zoccali C, Tripepi G, Benedetto FA, Parlongo S, Cataliotti A, Cutrupi S, Giacone G, Bellanuova I, Stancanelli B, Malatino LS, CREED Investigators. The cardiovascular risk extended evaluation diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int. 2001 Apr; 59(4):1559-66.
    
76. Mallamaci F, Zoccali C, Tripepi G, Benedetto FA, Parlongo S, Cataliotti A, Cutrupi S, Giacone G, Bellanuova I, Stancanelli B, Malatino LS, CREED Investigstors. The Cardiovascular Risk Extended Evaluation. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int. 2001 Apr; 59(4):1559-66.
    View PubMed
77. Cuzzola F, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Cataliotti A, Stancanelli B, Malatino L, Bellanuova I, Ferri C, Galletti F, Filigheddu F, Glorioso N, Strazzullo P, Zoccali C. Urinary adrenomedullin is related to ET-1 and salt intake in patients with mild essential hypertension. Salt Sensitivity Group of Italian Society of Hypertension. Am J Hypertens. 2001 Mar; 14(3):224-30.
    View PubMed
78. Malatino LS, Mallamaci F, Benedetto FA, Bellanuova I, Cataliotti A, Tripepi G, Zoccali C. Hepatocyte growth factor predicts survival and relates to inflammation and intima media thickness in end-stage renal disease. Am J Kidney Dis. 2000 Nov; 36(5):945-52.
    View PubMed
79. Malatino LS, Bellanuova I, Cataliotti A, Cuzzola F, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Mangiafico RA, Ferri C, Galletti F, Glorioso N, Strazzullo P, Zoccali C. Renal endothelin-1 is linked to changes in urinary salt and volume in essential hypertension. Salt Sensitivity Group of the Italian Society of Hypertension. J Nephrol. 2000 May-Jun; 13(3):178-84.
    View PubMed
80. Malatino LS, Benedetto FA, Mallamaci F, Tripepi G, Zoccali C, Parlongo S, Cutrupi S, Marino C, Panuccio V, Garozzo M, Candela V, Bellanuova I, Cataliotti A, Rapisarda F, Fatuzzo P, Bonanno G, Seminara G, Stancanelli B, Tassone F, Labate C. Smoking, blood pressure and serum albumin are major determinants of carotid atherosclerosis in dialysis patients. CREED Investigators. Cardiovascular Risk Extended Evaluation in Dialysis patients. J Nephrol. 1999 Jul-Aug; 12(4):256-60.
    View PubMed
81. Bellofiore S, Malatino LS, Sapienza MA, Bellanuova I, Cataliotti A, Di Maria GU. The relationship between cardiac output and posthyperventilation hyperpnoea in patients with essential hypertension. Eur Respir J. 1998 Nov; 12(5):1160-3.
    View PubMed
82. Malatino LS, Polizzi G, Garozzo M, Rapisarda F, Fatuzzo P, Bellanuova I, Cataliotti A, Brozzetti A, Neri S, Malfa PA, Cotroneo GB. Diagnosis of renovascular disease by extra- and intrarenal Doppler parameters. Angiology. 1998 Sep; 49(9):707-21.
    View PubMed
83. Tripepi G, Candela V, Fatuzzo P, Rapisarda F, Bonanno G, Seminara G, Stancanelli B, Benedetto FA, Mallamaci F, Cottini E, Giacone G, Cataliotti A, Labate C, Tassone F, Malatino LS, Zoccali C. Determinants of left ventricular hypertrophy in dialysis patients. (Italian). Giorn It Nefrol. 1998; 15:231-40.
    
84. Iannello S, Asmundo GO, Cataliotti A, Floridia S, Loreno M, Trovato G, Vintaloro G, Belfiore F. Vasculitic urticarioid syndrome. A clinical case and review of literature. Minerva Med (Italian). 1997; 88: 459-67.